Population
Humans (young and elderly subjects) and adult patients undergoing elective hip or knee replacement surgery
Design
Review
Authors
Loading...
May enable fixed dosing without monitoring; leaves open prospective validation across populations.
Rivaroxaban is an oral, direct factor Xa inhibitor with predictable pharmacokinetics and pharmacodynamics, allowing for fixed dosing without routine coagulation monitoring.
Reinhold Kreutz (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: